In pharmaceutical and aseptic manufacturing, SIP (Sterilization-in-Place) systems are essential for ensuring SAL (Sterility Assurance Level) and maintaining product safety. As GMP requirements continue to emphasize process control and data integrity, traditional SIP validation approaches are increasingly insufficient to meet modern expectations for risk management and full lifecycle traceability. As a result, the development of SIP programs and their performance qualification have become a key focus for pharmaceutical engineering and quality teams.
Against this backdrop, the Online Steam System Program Development and Performance Qualification Technical Exchange Conference was held on March 20, 2026, at Morimatsu 5S Beijing (Yizhuang) Branch. The event was designed to address key industry challenges, establish a professional platform for technical exchange, strengthen compliance in sterile manufacturing, and support the pharmaceutical industry in achieving efficient, high-quality development.
During the event, Validation Director Jia of Morimatsu LifeSciences’ Validation Consulting Division, delivered a keynote presentation. He provided a comprehensive overview of the latest regulatory expectations and industry guidelines, systematically outlining the four key stages of SIP validation: preparation, risk assessment, program development, and performance qualification. Through this exchange, participants gained a deeper understanding of the importance and urgency of implementing risk-based SIP program development and performance qualification.
The session also introduced the core capabilities of Morimatsu’s Validation Consulting Division. With a strong focus on GMP compliance, the team delivers end-to-end validation solutions, including domestic and international GMP consulting as well as full-scale validation execution. These services help clients strengthen aseptic manufacturing controls and improve audit readiness.
Validation consulting business scope
Following the keynote, engineering and quality leaders from participating pharmaceutical companies engaged in active, in-depth discussions with Morimatsu’s validation team on key topics such as SIP program development and performance qualification. Participants raised practical questions based on real-world sterile manufacturing challenges, while Morimatsu’s experts provided detailed responses grounded in extensive project experience.
The discussions helped build consensus, offering practical support for strengthening aseptic manufacturing controls and improving audit readiness, while also driving compliance upgrades and quality improvements across the industry.
Morimatsu LifeSciences will continue to focus on key technical challenges and compliance needs in pharmaceutical aseptic manufacturing, regularly hosting industry seminars and technical exchange events across a range of topics. These initiatives aim to create a high-quality platform for sharing advanced technologies and best practices. We look forward to engaging and collaborating with more partners across the pharmaceutical industry, supporting sustainable growth through our expertise.
About Morimatsu LifeSciences
Morimatsu LifeSciences is one of the key business segments of Morimatsu International Holdings Company Limited (Morimatsu International, Stock Code: 2155.HK). It primarily consists of Shanghai Morimatsu Pharmaceutical Equipment Engineering Co., Ltd., Morimatsu (Suzhou) LifeSciences Company Limited, Shanghai Morimatsu Biotechnology Co., Ltd., Shanghai Mori-Biounion Technology Co., Ltd., Shanghai MoriSora Technology Co., Ltd., Bioengineering AG and Pharmadule Morimatsu AB, along with their subsidiaries.
We specialize in providing core equipment, process systems, and comprehensive digital-intelligent plant solutions along with corresponding services for industries including pharmaceuticals, biopharmaceuticals, medical aesthetics, fast-moving consumer goods (FMCG, including cosmetics, food, health products, etc.), and data centers. The company boasts an elite team composed of seasoned experts across multiple fields, including process R&D, engineering design, high-end manufacturing, validation consulting, production execution, and digital-intelligent operations. The team members possess extensive experience in industries such as pharmaceuticals, biopharmaceuticals, medical aesthetics, FMCG, and data centers. They are well-versed in the characteristics and process flows of diverse products, enabling them to provide customized process solutions tailored to client needs from the conceptual design stage onward.
Morimatsu LifeSciences has established a global strategic presence, with advanced R&D, design centers, and manufacturing bases across different countries and regions, complemented by a comprehensive service network covering Europe, America, Asia-Pacific, and emerging markets. The company's international professional team has successfully delivered customized solutions to over 40 countries and regions, accumulating rich experience in global project execution.
As a multinational enterprise mastering core process technologies, modular construction, and digital intelligent plant expertise, Morimatsu LifeSciences is committed to meeting the production equipment demands of global industries, including pharmaceuticals, biopharmaceuticals, medical aesthetics, FMCG, and data centers. Through continuous innovation and optimization, the company supports domestic enterprises in accelerating the strategic localization of core and high-end equipment, driving industry advancement. Simultaneously, the company actively expands overseas markets, deepening its "globalization" business development strategy to contribute Morimatsu's expertise to the global life sciences and related industries.
